MYCN and neuroblastoma: The developed signature also retained its independent prognostic effect in multivariate analysis with clinicopathological variables, including age at diagnosis, MYCN amplification status, and INSS stage–all of which are used to varying degrees to stratify neuroblastoma patient risk.